<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>They often transform to <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), which is difficult to treat and carries a dismal prognosis </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> is a hypomethylating agent approved for the treatment of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with 20% to 30% bone marrow blasts, according to World Health Organization classification </plain></SENT>
<SENT sid="3" pm="."><plain>The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>